Integra LifeSciences Holdings Corporation (NASDAQ: IART) recently received a number of ratings updates from brokerages and research firms:

  • 8/2/2017 – Integra LifeSciences Holdings Corporation was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Integra exited the second quarter of 2017 on somewhat disappointing note with earnings in line with the Zacks Consensus Estimate and revenues missing the mark. We are concerned about the currency headwind that is expected to affect Integra’s financial performance in the rest of 2017. Also, contraction in adjusted operating margin and adjusted gross margin adds to the woes. On a positive note, the strong year over year increase in revenue on the back of solid performance of its Orthopedics and Tissue Technologies’ segment buoys optimism. We believe the company’s recent product diversification bolstered investors’ confidence, thereby boosting the stock price further. Overall, in the last three months, Integra Lifesciences has been consistently trading above the broader industry. However, the recent purchase of Derma Sciences and impending buyout of Codman Neurosurgery has made the stock’s valuation stretched.”
  • 7/27/2017 – Integra LifeSciences Holdings Corporation was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Integra exited the second quarter of 2017 on somewhat disappointing note with earnings in line with the Zacks Consensus Estimate and revenues missing the mark. We are concerned about the currency headwind that is expected to affect Integra’s financial performance in the rest of 2017. Also, contraction in adjusted operating margin and adjusted gross margin adds to the woes. On a positive note, the strong year over year increase in revenue on the back of solid performance of its Orthopedics and Tissue Technologies’ segment buoys optimism. We believe the company’s recent product diversification bolstered investors’ confidence, thereby boosting the stock price further. Overall, in the last three months, Integra Lifesciences has been consistently trading above the broader industry. However, the recent purchase of Derma Sciences and impending buyout of Codman Neurosurgery has made the stock’s valuation stretched.”
  • 7/27/2017 – Integra LifeSciences Holdings Corporation had its price target raised by analysts at Raymond James Financial, Inc. from $51.00 to $55.00. They now have an “outperform” rating on the stock.
  • 7/26/2017 – Integra LifeSciences Holdings Corporation was given a new $65.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/26/2017 – Integra LifeSciences Holdings Corporation had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 7/24/2017 – Integra LifeSciences Holdings Corporation was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/10/2017 – Integra LifeSciences Holdings Corporation had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
  • 6/29/2017 – Integra LifeSciences Holdings Corporation is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $65.00 price target on the stock.
  • 6/28/2017 – Integra LifeSciences Holdings Corporation was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Over the last one month, Integra Lifesciences has been trading above the broader Medical-Biomed/Genetics sub-industry. However, the decision to buy Derma Sciences and Codman Neurosurgery has made the stock’s valuation stretched. Further, the company saw a rise in operating expenses. Also foreign exchange and competitive landscape woes continue to pose threats. On a positive note, during the last reported first quarter, the company recorded solid year-over-year improvement on the revenue front. This indicates healthy growth via organic and inorganic means across all segments. We believe the company’s recent product diversification bolstered investors’ confidence, thereby boosting the stock price further. Of late, the company launched IDRT product for dermal repair and SurgiMend MP collagen matrix for hernia repair. We are looking forward to its tie up with aap Implantate AG.”
  • 6/24/2017 – Integra LifeSciences Holdings Corporation was given a new $60.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 6/9/2017 – Integra LifeSciences Holdings Corporation had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $60.00 price target on the stock, up previously from $48.00.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, meeting the consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The firm had revenue of $282.16 million for the quarter, compared to analyst estimates of $283.58 million. During the same period last year, the firm earned $0.40 EPS. The business’s quarterly revenue was up 13.2% compared to the same quarter last year.

In other news, Director Stuart Essig sold 135,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $49.90, for a total value of $6,736,500.00. Following the sale, the director now directly owns 2,077,475 shares in the company, valued at approximately $103,666,002.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Donald E. Morel, Jr. purchased 10,000 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Friday, August 4th. The stock was bought at an average price of $49.25 per share, for a total transaction of $492,500.00. Following the completion of the purchase, the director now owns 29,612 shares in the company, valued at approximately $1,458,391. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 17,550 shares of company stock worth $864,842. 21.50% of the stock is currently owned by corporate insiders.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.